Epilepsy Drugs

Epilepsy Drugs

Global Epilepsy Drugs Market to Reach $5.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Epilepsy Drugs estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$5.8 Billion by 2027, growing at a CAGR of 3.3% over the analysis period 2020-2027. First Generation, one of the segments analyzed in the report, is projected to record a 2.5% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Second Generation segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 5.2% CAGR

The Epilepsy Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 5.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Third Generation Segment to Record 3.9% CAGR

In the global Third Generation segment, USA, Canada, Japan, China and Europe will drive the 3.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.2 Billion in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$752.6 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories, Inc.
  • Cephalon, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi Aventis S.A.
  • Shire PLC
  • Tansna Therapeutics, Inc.
  • UCB Pharma, Inc.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Current & Future Analysis for Epilepsy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Epilepsy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
TABLE 4: World Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 7: World Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 10: World Current & Future Analysis for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Third Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 13: World Current & Future Analysis for Narrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Narrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Narrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 16: World Current & Future Analysis for Broad by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Broad by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Broad by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
TABLE 19: USA Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 20: USA Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 21: USA 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 22: USA Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 23: USA Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 24: USA 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
CANADA
TABLE 25: Canada Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 26: Canada Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 27: Canada 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 28: Canada Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 29: Canada Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 30: Canada 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
JAPAN
TABLE 31: Japan Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 32: Japan Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 33: Japan 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 34: Japan Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 35: Japan Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 36: Japan 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
CHINA
TABLE 37: China Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 38: China Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 39: China 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 40: China Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 41: China Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 42: China 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
EUROPE
TABLE 43: Europe Current & Future Analysis for Epilepsy Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 44: Europe Historic Review for Epilepsy Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 45: Europe 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
TABLE 46: Europe Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 47: Europe Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 48: Europe 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 49: Europe Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 50: Europe Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 51: Europe 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
FRANCE
TABLE 52: France Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 53: France Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 54: France 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 55: France Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 56: France Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 57: France 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
GERMANY
TABLE 58: Germany Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 59: Germany Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 60: Germany 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 61: Germany Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 62: Germany Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 63: Germany 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
ITALY
TABLE 64: Italy Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 65: Italy Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 66: Italy 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 67: Italy Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 68: Italy Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 69: Italy 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
UNITED KINGDOM
TABLE 70: UK Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 71: UK Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 72: UK 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 73: UK Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 74: UK Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 75: UK 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
SPAIN
TABLE 76: Spain Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 77: Spain Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 78: Spain 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 79: Spain Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 80: Spain Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 81: Spain 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
RUSSIA
TABLE 82: Russia Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 83: Russia Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 84: Russia 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 85: Russia Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 86: Russia Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 87: Russia 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
REST OF EUROPE
TABLE 88: Rest of Europe Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 89: Rest of Europe Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 90: Rest of Europe 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 91: Rest of Europe Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 92: Rest of Europe Historic Review for Epilepsy Drugs by Spectrum Type - Narrow and Broad Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 93: Rest of Europe 15-Year Perspective for Epilepsy Drugs by Spectrum Type - Percentage Breakdown of Value Sales for Narrow and Broad for the Years 2012, 2020 & 2027
ASIA-PACIFIC
TABLE 94: Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 95: Asia-Pacific Historic Review for Epilepsy Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 96: Asia-Pacific 15-Year Perspective for Epilepsy Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
TABLE 97: Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 98: Asia-Pacific Historic Review for Epilepsy Drugs by Drug - First Generation, Second Generation and Third Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 99: Asia-Pacific 15-Year Perspective for Epilepsy Drugs by Drug - Percentage Breakdown of Value Sales for First Generation, Second Generation and Third Generation for the Years 2012, 2020 & 2027
TABLE 100: Asia-Pacific Current & Future Analysis for Epilepsy Drugs by Spectrum Type - Narrow and Broad - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook